Shots:

• The P-III RECOVERY trial evaluating REGEN-COV (8-000 mg) vs usual care alone in seronegative patients with COVID-19 demonstrates 20% reduction in risk of death in patients failing to exhibit a natural antibody response
• The 1EPs showed 20% reduction in all-cause mortality- no longer significant effect on 28-day mortality on combining larger seropositive group (also those with unknown status) with seronegative patients
• Additionally- lower risk of composite EP progression of invasive mechanical ventilation or death was observed (30% vs 37%). The company will share new data with regulatory authorities & request FDA to expand the current EUA to other populations

  | Ref: PR Newswire | Image: The Print